4/A//SEC Filing
MOULDER LEON O JR 4/A
Accession 0001104659-24-100765
CIK 0001953926other
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 8:54 PM ET
Size
23.0 KB
Accession
0001104659-24-100765
Insider Transaction Report
Form 4/AAmended
MOULDER LEON O JR
DirectorChief Executive Officer
Transactions
- Conversion
Common Stock
2024-09-16+164,523→ 1,280,022 total(indirect: See Footnote) - Conversion
Common Stock
2024-09-16+372,017→ 1,652,039 total(indirect: See Footnote) - Conversion
Series B Convertible Preferred Stock
2024-09-16−3,230,268→ 0 total(indirect: See Footnote)→ Common Stock (372,017 underlying) - Conversion
Common Stock
2024-09-16+48,254→ 161,155 total - Conversion
Series B Convertible Preferred Stock
2024-09-16−418,996→ 0 total→ Common Stock (48,254 underlying) - Award
Stock Option (Right to Buy)
2024-09-12+1,486,000→ 1,486,000 totalExercise: $17.00Exp: 2034-09-11→ Common Stock (1,486,000 underlying) - Conversion
Common Stock
2024-09-16+108,381→ 112,901 total - Conversion
Series Seed Convertible Preferred Stock
2024-09-16−1,428,571→ 0 total(indirect: See Footnote)→ Common Stock (164,523 underlying) - Conversion
Series A Convertible Preferred Stock
2024-09-16−941,088→ 0 total→ Common Stock (108,381 underlying)
Footnotes (6)
- [F1]On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F2]This amendment is being filed solely to correct the previously reported "Amount of Securities Beneficially Owned Following Reported Transactions." This amended Form 4 does not report any new transactions or otherwise modify the transaction details that were previously reported.
- [F3]Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F4]On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F5]On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- [F6]The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service.
Documents
Issuer
Zenas BioPharma, Inc.
CIK 0001953926
Entity typeother
Related Parties
1- filerCIK 0001228865
Filing Metadata
- Form type
- 4/A
- Filed
- Sep 16, 8:00 PM ET
- Accepted
- Sep 17, 8:54 PM ET
- Size
- 23.0 KB